TW202114742A - 前列腺特異性膜抗原(psma)配體及其用途 - Google Patents

前列腺特異性膜抗原(psma)配體及其用途 Download PDF

Info

Publication number
TW202114742A
TW202114742A TW109122386A TW109122386A TW202114742A TW 202114742 A TW202114742 A TW 202114742A TW 109122386 A TW109122386 A TW 109122386A TW 109122386 A TW109122386 A TW 109122386A TW 202114742 A TW202114742 A TW 202114742A
Authority
TW
Taiwan
Prior art keywords
compound
formula
psma
group
cancer
Prior art date
Application number
TW109122386A
Other languages
English (en)
Chinese (zh)
Inventor
馬里西歐 Ｆ 馬里亞尼
羅倫薩 弗卡薩
戴妮娜 奇可
馬丁 吉伯特 龐波
桑吉塔 雷
Original Assignee
義大利商先進艾斯雷特應用（義大利）公司
美國約翰赫金斯大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 義大利商先進艾斯雷特應用（義大利）公司, 美國約翰赫金斯大學 filed Critical 義大利商先進艾斯雷特應用（義大利）公司
Publication of TW202114742A publication Critical patent/TW202114742A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/38—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW109122386A 2019-07-02 2020-07-02 前列腺特異性膜抗原(psma)配體及其用途 TW202114742A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19184015.6 2019-07-02
EP19184015 2019-07-02

Publications (1)

Publication Number Publication Date
TW202114742A true TW202114742A (zh) 2021-04-16

Family

ID=67145647

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109122386A TW202114742A (zh) 2019-07-02 2020-07-02 前列腺特異性膜抗原(psma)配體及其用途

Country Status (16)

Country Link
US (1) US20230226227A1 (https=)
EP (1) EP3993837A1 (https=)
JP (2) JP7805170B2 (https=)
KR (1) KR20220044496A (https=)
CN (3) CN120441497A (https=)
AR (1) AR119331A1 (https=)
AU (3) AU2020299974A1 (https=)
BR (1) BR112021026812A2 (https=)
CA (1) CA3144557A1 (https=)
CL (1) CL2021003525A1 (https=)
CO (1) CO2021017708A2 (https=)
IL (1) IL289039B1 (https=)
MX (1) MX2022000136A (https=)
PH (1) PH12021553284A1 (https=)
TW (1) TW202114742A (https=)
WO (1) WO2021001360A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230330278A1 (en) * 2020-04-29 2023-10-19 Novartis Ag Methods for radiolabelling psma binding ligands and their kits
KR20260040237A (ko) 2023-07-21 2026-03-24 노파르티스 아게 Psma 표적 방사성 리간드 치료 요법
WO2025125469A1 (en) 2023-12-13 2025-06-19 Swiss Rockets Ag Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271026A1 (en) 2000-07-11 2002-01-21 Bml, Inc. Remedies for bone diseases
WO2013022797A1 (en) * 2011-08-05 2013-02-14 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
LT4095130T (lt) * 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
HRP20240215T1 (hr) * 2016-03-22 2024-04-26 The Johns Hopkins University Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate
WO2018222778A1 (en) * 2017-05-30 2018-12-06 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
KR20250126870A (ko) * 2018-02-06 2025-08-25 더 존스 홉킨스 유니버시티 암 방사선 치료를 위한 psma 표적 방사성 할로겐화 우레아-폴리아미노카복실레이트
WO2020028323A1 (en) * 2018-07-30 2020-02-06 The Johns Hopkins Universtiy Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy

Also Published As

Publication number Publication date
US20230226227A1 (en) 2023-07-20
AU2024200850B2 (en) 2025-09-04
CN120441497A (zh) 2025-08-08
JP7805170B2 (ja) 2026-01-23
PH12021553284A1 (en) 2022-08-01
AU2024200850A1 (en) 2024-02-29
JP2022538478A (ja) 2022-09-02
BR112021026812A2 (pt) 2022-02-22
JP2025165975A (ja) 2025-11-05
CN120441498A (zh) 2025-08-08
IL289039B1 (en) 2026-03-01
AU2025271182A1 (en) 2025-12-18
IL289039A (en) 2022-02-01
CL2021003525A1 (es) 2022-10-21
CA3144557A1 (en) 2021-01-07
CN114341118A (zh) 2022-04-12
KR20220044496A (ko) 2022-04-08
MX2022000136A (es) 2022-04-27
EP3993837A1 (en) 2022-05-11
AU2020299974A1 (en) 2022-01-27
AR119331A1 (es) 2021-12-09
CO2021017708A2 (es) 2022-05-20
WO2021001360A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
US20250057993A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
CN111285918B (zh) 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物
US8623322B2 (en) Non-invasive diagnostic agents and methods of diagnosing infectious disease
JP2018058847A (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
JP2025165975A (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
EP4474379A1 (en) Peptide urea derivative, pharmaceutical composition containing peptide urea derivative, and application of peptide urea derivative
AU2016416524A1 (en) Radioactive phospholipid metal chelates for cancer imaging and therapy
EP2643301B1 (fr) Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
JP5322651B2 (ja) シンチグラフィー法
JP7608378B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
ES2433482T3 (es) Método de gammagrafía
CN120349373A (zh) 一种含氮化合物及其制备方法与用途
WO2025153101A1 (zh) 一种含氮化合物及其制备方法与用途